论文部分内容阅读
靛玉红(Indirubin)是我国首创的有效抗白血病药物。1977年以来临床应用于慢性粒细胞型白血病(以下简称慢粒)的疗效已得到肯定。单用此药所得的缓解率为59.87％,有效率87.26％。为了提高疗效,我院在1982年4月至1982年12月,8个月内单独试用靛玉红B_2治疗慢粒6例,现将治疗效果小结如下: 资料与方法 一、病例选择:6例慢粒,男性5例,女性1例。年龄16—45岁,平均28.5岁。5例初
Indirubin is the first effective anti-leukemia drug in our country. Since 1977, the clinical application of chronic myelogenous leukemia (hereinafter referred to as CML) has been affirmed. The drug alone with the rate of relief was 59.87%, the effective rate of 87.26%. In order to improve the curative effect, our hospital in April 1982 to December 1982, 8 months trial of indirubin B_2 alone in 6 cases of CML, the treatment is summarized as follows: Materials and Methods A case selection: 6 cases CML, 5 males and 1 females. Age 16-45 years old, average 28.5 years old. 5 cases early